Strategic Update: Marksans Pharma Acquires QliniQ BV for €7.5M

$MARKSANS Overview Marksans Pharma Ltd. has signed a definitive agreement to acquire 100% of the share capital of QliniQ BV, a Netherlands-based pharmaceutical firm, for a total consideration of €7.5 million. This transaction accelerates the company’s forward-integration strategy and significantly enhances its operational footprint within highly regulated European markets. Strategic Synergies & Value Creation This acquisition grants Marksans Pharma immediate, direct access to the Dutch pharmaceutical market while establishing robust in-house sales, marketing, and distribution capabilities across the broader European Union. QliniQ brings an established, highly valuable network of relationships with wholesalers, retail pharmacies, hospitals, and critical insurer-led tender channels. For investors, this infrastructure translates into a powerful, ready-made platform to independently commercialize Marksans Pharma’s existing and future pipeline products throughout Europe, reducing reliance on third parties and driving margin expansion. Target Profile & Financial Accretion QliniQ operates a resilient portfolio of niche pharmaceutical products and medical devices, strategically targeting segments with consistent demand, including women’s health, dermatology, and respiratory care. Financially, the acquisition is highly accretive. For the year ended December 2025, QliniQ reported robust revenues of €9.35 million and a net profit of €1.01 million. The firm has demonstrated exceptional top-line momentum, achieving a revenue CAGR of approximately 41% between FY23 and FY25. Crucially, QliniQ operates with a pristine, debt-free balance sheet, ensuring this acquisition adds immediate fundamental value without introducing leverage risk.